^
    Back
    Association details:
    Biomarker:PTEN H93D
    Cancer:Melanoma
    Drug:Tafinlar (dabrafenib) (BRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Cancer Discov
    Title:

    The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma

    Excerpt:
    Patient 1 had a PTEN H93D missense mutation in the pre-treatment tumor but was on therapy for 66 weeks and achieved a partial response.
    DOI:
    10.1158/2159-8290.CD-13-0617